-
About UsBeijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs. -
R&D and ProductsPrimarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases. -
Investor RelationsGuided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
2008
June 3
The NL003 project has been approved by the National Medical Products Administration and has officially entered Phase I clinical trials.
June 16
Beijing Northland Biotechnology Co., Ltd. has successfully been reorganized into Beijing Northland Biotechnology Co., Ltd., with the registered capital increasing from the original 2 million yuan to 9.5 million yuan.
October 31st
Phase I clinical trial for Project NL003 has been initiated.
December 31st
Through the new version of the high-tech enterprise certification.
Share to:
Friendly Links: Baidu | NORTHLAND
Contact Information
Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing
Follow Us
Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.
Web site
NL-BIO
NL003
NL005